Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Policy / Regulatory

China Proposes Healthcare Security Law to Strengthen Medical Insurance System

Fineline Cube Jun 30, 2025

China’s National Healthcare Security Administration (NHSA) last week released the “Healthcare Security Law (draft proposal)”,...

Company Deals

QuantumPharm and Pfizer Expand Collaboration on Advanced Molecular Simulation Platform

Fineline Cube Jun 30, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), has announced an expansion of its...

Company Deals

BlissBio Inc. Files for Hong Kong IPO to Advance Oncology-Focused ADC Pipeline

Fineline Cube Jun 30, 2025

Hangzhou-based oncology-focused clinical-stage biotech BlissBio Inc. has filed for an initial public offering (IPO) with...

Policy / Regulatory

FDA Removes REMS Requirements for BCMA- and CD19-Targeted CAR-T Therapies

Fineline Cube Jun 30, 2025

The U.S. Food and Drug Administration (FDA) last week announced the removal of Risk Evaluation...

Company Deals

ProFound Therapeutics and Novartis Forge Four-Year Partnership for Cardiovascular Drug Targets

Fineline Cube Jun 30, 2025

US-based ProFound Therapeutics announced a four-year partnership with Swiss giant Novartis (NYSE: NVS) to discover...

Company Deals

Diagens Biotech’s AI Imaging Platform iMedImage Makes Hong Kong IPO Debut

Fineline Cube Jun 30, 2025

China-based Hangzhou Diagens Biotechnology Co., Ltd. has filed for an initial public offering (IPO) with...

Company Drug

Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections

Fineline Cube Jun 30, 2025

US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China’s...

Company Drug

Gilead’s Lenacapavir Approved in Hainan for HIV-1 Pre-Exposure Prophylaxis

Fineline Cube Jun 30, 2025

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its HIV pre-exposure prophylaxis (PrEP) drug, lenacapavir,...

Company Deals

GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success

Fineline Cube Jun 30, 2025

China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the...

Company Deals

DK Medtech Partners with Mozarc Medical to Enhance Hemodialysis Access Solutions

Fineline Cube Jun 28, 2025

Suzhou-based DK Medical Technology Co. Ltd., a developer of vascular intervention balloon products, has entered...

Company Drug

ACIP Recommends MSD’s Enflonsia for Infants Under 8 Months to Prevent RSV

Fineline Cube Jun 27, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) revealed that the Advisory Committee...

Others

Viatris Announces Positive Results in VEGA-3 Trial for MR-141 Presbyopia Treatment

Fineline Cube Jun 27, 2025

US-based Viatris (NASDAQ: VTRS) announced positive topline results from the second pivotal Phase III VEGA-3...

Company Medical Device

Jenscare’s LuX-Valve Plus Shows Promising Results in Global TRINITY Study

Fineline Cube Jun 27, 2025

Ningbo-based structural heart disease device maker Jenscare Scientific Co., Ltd (HKG: 9877) announced positive 30-day...

Company Drug

Innovent Biologics’ Mazdutide Gets NMPA Nod for Weight Management

Fineline Cube Jun 27, 2025

China’s National Medical Products Administration (NMPA) has approved Innovent Biologics, Inc.’s (HKG: 1801) mazdutide (IBI362),...

Company Deals

Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development

Fineline Cube Jun 27, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing...

Policy / Regulatory

China Raises Subsidy for Basic Public Health Services, Targets Vulnerable Groups

Fineline Cube Jun 27, 2025

China’s National Health Commission (NHC) released the “Notice on Improving Basic Public Health Services in...

Company Drug

Hua Dong Medicine’s HDM2020 Gains NMPA Approval for Clinical Trials

Fineline Cube Jun 27, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Drug

Cutia Therapeutics’ Phase III Results for Lidocaine-Tetracaine Cream to be Presented at CSD Meeting

Fineline Cube Jun 27, 2025

Cutia Therapeutics (HKG: 2487), a dermatology specialist, is set to present the Phase III clinical...

Company Deals

Novartis Completes Acquisition of Regulus Therapeutics for ADPKD Treatment

Fineline Cube Jun 27, 2025

Swiss giant Novartis (NYSE: NVS) announced the completion of its acquisition of U.S.-based Regulus Therapeutics....

Company Drug

Sino Biopharmaceutical’s LM-108 Gains CDE BTD for Gastric Adenocarcinoma

Fineline Cube Jun 27, 2025

Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has obtained Breakthrough Therapy Designation (BTD) from...

Posts pagination

1 … 158 159 160 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.